Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 5,264 |
|
|||||
| News | (1) | ||||||
| Day High | 1.2899 | Low High |
|||||
| Day Low | 1.15 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| RenovoRx Inc | RNXT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.03 | 2.52% | 1.22 | 17:19:18 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.19 | 1.15 | 1.2899 | 1.22 | 1.19 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 58 | 5,264 | $ 1.21 | $ 6,381 | - | 0.5306 - 3.29 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 6 | $ 1.16 | USD |
RenovoRx Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 13.05M | 10.69M | - | 0 | -10.23M | -0.96 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
RenovoRx News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RNXT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.2139 | 1.3584 | 1.10 | 1.22 | 24,259 | 0.0061 | 0.50% |
| 1 Month | 1.44 | 1.56 | 1.10 | 1.19 | 66,298 | -0.22 | -15.28% |
| 3 Months | 1.09 | 1.86 | 1.00 | 1.37 | 52,124 | 0.13 | 11.93% |
| 6 Months | 1.09 | 2.35 | 0.5306 | 1.41 | 67,398 | 0.13 | 11.93% |
| 1 Year | 3.00 | 3.29 | 0.5306 | 2.22 | 189,610 | -1.78 | -59.33% |
| 3 Years | 8.25 | 16.74 | 0.5306 | 7.74 | 472,357 | -7.03 | -85.21% |
| 5 Years | 8.25 | 16.74 | 0.5306 | 7.74 | 472,357 | -7.03 | -85.21% |
RenovoRx Description
| RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem. |
